Clinical Study

Swog S1607- A Phase II Study Of Combining Talimogene Laherparepvec (T-Vec) (Nsc-785349) And Mk-3475 (Pembrolizumab) (Nsc-776864) In Patients With Advanced Melanoma Who Have Progressed On Anti-Pd1/L1 Based Therapy

Posted Date: Jul 8, 2020

  • Investigator: Rekha Chaudhary
  • Specialties: Cancer, Oncology, Skin Cancer
  • Type of Study: Drug

The goal of this study is evaluate the objective response rate (confirmed complete and partial responses) of treatment with talimogene laherparepvec in combination with MK-3475, (pembrolizumab) following progression on prior anti-PD-1 or anti-PD-L1 therapy alone or in combination with other agents different from talimogene laherparepvec.

Criteria:

To Be Eligible: Pathologically Confirmed Stage Iv Or Unresectable Stage Iii Melanoma, Measurable Disease, Zubrod Performance Status = 2, Had Prior Treatment With Anti-Pd-1 Or Anti-Pd-L1 Agents And Have Documented Disease Progression, No Prior Treatment With Talimogene Laherparepvec, No Organ Allografts, No Active Or Past Infection Or Illness That Could Impact Study Treatment,

Keywords:

Melanoma

For More Information:

Uc Cancer Center
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.